| Molecule | Study type | Mechanisms | Refs. |
| Quercetin | In vitro | Reduces TNF-α-induced expression of ICAM-1 Inhibits VCAM-1 and E-selectin expression, as well as COX-2 and iNOS Activates the expression of HIF-1α and regulates glucose and hypoxia homeostasis | [31] [32] [33] | Animal | Induces reduction of fatty acid and triacylglycerol synthesis and inhibits LDL oxidation Increases Akt phosphorylation, eNOS phosphorylation, and NO production Increases expression of VEGF Downregulates cytochrome p450 2b genes, steroid, and cholesterol synthesis | [26, 27] [28, 29] [30] [34, 35] | Human | Reduces cellular senescence | [25] | Catechin | In vitro | Improves redox imbalance and mitochondrial dysfunction by AMPK and ACC phosphorylation Inhibits TNF-α-induced insulin signaling pathway and induces PGC-1α expression | [47] [48] | Animal | Exerts beneficial effects on aortic expression of endothelial dysfunction biomarkers (VCAM-1, ICAM-1, E-selectin, LOX-1, TNF-α, and IL-6) | [46] | Human | Increases flow-mediated dilation, reduces pulse wave velocity and diastolic blood pressure Increases thermogenesis, reduces adipogenesis, and promotes fat oxidation | [39–41] [42, 43] | Resveratrol | In vitro | Reduces cholesterol peroxidation, reactive oxygen species levels, and platelet aggregation by promoting vasodilation through NO synthesis and inhibition of endothelin-1 Lowers proinflammatory mediators IL-8 and ICAM-1 in TNF-α-activated endothelial cells | [50–52] [53] | Animal | Ameliorates endothelial dysfunction through PPARδ and SIRT1 activation Increases expression of AMPKα, activates fatty acid mobilization and degradation, and inhibits fatty acid synthesis | [56] [22] | Human | Increases branchial flow-mediated dilation response Rises the expression of AMPK, SIRT1, and PGC-1α protein levels | [54, 55] [59] | Urolithin | In vitro | Inhibits monocyte adhesion, endothelial cell migration, and CCL-2 and IL-8 expressions Inhibits iNOS and decreases proinflammatory cytokines expression (IL-1β, TNF-α, and IL-6) Improves NO production and eNOS activity in a dose-dependent manner and suppresses the expression of TNF-α, IL-6, ICAM-1, MCP-1, and endothelin 1 and increases PPAR-γ mRNA levels | [61] [63, 64] [66] | Animal | Reduces LDL cholesterol, triglycerides, free fatty acids, and oxidative stress Reduces ventricular hypertrophy and arrhythmia | [67, 68] [68] | Human | Improves endothelial function through improvements in flow-mediated dilation | [65] |
|
|